Head-to-head · WeighScore
Tell Her Doc vs Zealthy
The verdict
Tell Her Doc takes it — 57.4/100 to 46.7/100.
Tell Her Doc grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Tell Her Doc is a women-focused, self-pay telehealth program for compounded GLP-1 weight loss — compounded semaglutide and tirzepatide in injection, oral, and orally-dissolving-tablet forms, plus microdoses.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Tell Her Doc | Zealthy |
|---|---|---|
| WeighScore | 57.4/100 | 46.7/100 |
| Grade | C | C |
| Scorecard rank | #400 | #496 |
| Semaglutide | $269/mo (microdose tier, plus a separate fee, compounded) | $286/mo (starting dose, plus a separate fee, compounded) |
| Tirzepatide | Not disclosed | $351/mo (starting dose, plus a separate fee, compounded) |
| Coverage | All 50 states | 34 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #400 · C
Strengths
- Full compounded GLP-1 lineup — semaglutide and tirzepatide in injection, oral and orally-dissolving-tablet forms, plus microdoses
- Names its compounding pharmacy partner (Casa Pharma RX), which is independently listed in our pharmacy registry
- No monthly membership, cancel anytime, free discreet shipping; HSA/FSA eligible with buy-now-pay-later plans
- Serves patients in all 50 states via a private online consultation
Where it loses points
- 'All sales are final' — no refunds once medication has left the pharmacy
- Exact price is plan-dependent, shown after you pick a product; advertised 'starting at $269', with a lower $140 intro on oral semaglutide
- References LegitScript but without an independently verifiable seal — we couldn't confirm certification
- Compounded semaglutide and tirzepatide only — no brand-name (Wegovy/Zepbound) options
- Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name
Graded #496 · C
Strengths
- Serves 34 states — meaningful nationwide footprint
- Asynchronous model removes friction for patients who don't want a video visit
- Independent licensed prescribers retain full clinical authority
Where it loses points
- Active Novo Nordisk false-advertising lawsuit alleging trademark infringement and marketing compounded drugs as FDA-approved alternatives
- Active DOJ/FTC enforcement alleging undisclosed subscription terms, locked cancellation, and unauthorized health-data sharing
- Founder previously ran Cerebral, which settled with the FTC in 2024 over similar deceptive practices
- Recently rebranded to Gronk Inc. amid active enforcement
- FDA issued this company a warning letter dated 1 September 2025; the letter is public in FDA's warning-letter database
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.